Shots: The P-IIIb ASCEND study will evaluate the clinical outcomes & safety of the higher doses of nusinersen in 135 patients aged 5-39yrs. with SMA prior treated with Evrysdi at […]readmore
Tags : Spinraza
In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits […]readmore
Shots: The P-II/III DEVOTE study will evaluate the higher doses of Spinraza in 126 patients with SMA of all ages. The three-part study will include an open-label safety study followed […]readmore
Shots: The P-II NURTURE study involves assessing of Spinraza in comparison to the natural history of the disease in 25 pre-symptomatic infants with SMA The P-II NURTURE study resulted in […]readmore
Shots: The approval is based on P-II NURTURE study results assessing Spinraza in 300 infant patients who were genetically diagnosed with SMA and had not experienced any symptoms by the […]readmore